Numerous studies have identified and assessed biomarker alterations, such as those in mannose-6-phosphate (MPR) [34], tumor-reactive T cells [35], and PD-L1 [35], to assist in determining the ideal time to provide anti-PD-1/L1 therapy. Here, CD274 is linked to neoplasm.